Results 81 to 90 of about 3,496 (176)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY

Рациональная фармакотерапия в кардиологии, 2015
Indirect anticoagulants effectively prevent thromboembolic complications in patients with high risk of their development. It was proven in multicenter controlled studies.
D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes   +4 more
doaj   +1 more source

The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population

Research in Pharmaceutical Sciences, 2017
The genetic factors are determinants in required dosage changes of warfarin among which are polymorphisms of CYP2C9 and VKORC1 genes. The present study aimed to determine the allele and genotype frequency of CYP2C9 and VKORC1 genes in Birjand population. This study was conducted on 120 individuals who referred to Imam Reza and Vali-Asr hospitals for PT/
Fariba Emadian Razavi, Asghar Zarban, Fatemeh Hajipoor, Mohsen Naseri   +3 more
openaire   +4 more sources

NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2018
Aim. To evaluate adherence to treatment, mutations of the hemostatic system and food preferences as predictors of choice of optimal anticoagulant therapy in patients with atrial fibrillation (AF).Material and methods.
Ju. P. Skirdenko, N. A. Nikolayev
doaj   +1 more source

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy

International Journal of Hematology-Oncology and Stem Cell Research, 2016
Background: Although catalytic properties of different genetic polymorphisms of VKORC1 and CYP2C9 products have been identified, there is limited study available regarding warfarin dose requirement in Iranian patient population.
Behzad Poopak, Saghar Rabieipoor, Nazila Safari, Emadedin Naraghi, Fatemeh Sheikhsofla, Gelareh Khosravipoor   +5 more
doaj  

Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland

Clinical Epidemiology, 2021
Anna-Leena Vuorinen,1 Mika Lehto,2,3 Mikko Niemi,4,5 Kari Harno,6 Juha Pajula,1 Mark van Gils,1 Jaakko Lähteenmäki7 1VTT Technical Research Centre of Finland, Tampere, Finland; 2Heart and Lung Center, Helsinki University Hospital, Helsinki ...
Vuorinen AL, Lehto M, Niemi M, Harno K, Pajula J, van Gils M, Lähteenmäki J   +6 more
doaj  

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population

Therapeutics and Clinical Risk Management, 2017
LiQun Jia,1 Zanxin Wang,1,2 Jianlong Men,3 Heng Cai,4 Minxin Wei2 1Department of Cardiovascular Surgery, Tianjin Medical University General Hospital, Tianjin, 2Department of Cardiac Surgery, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen ...
Jia LQ, Wang Z, Men J, Cai H, Wei M
doaj  

Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants

Acta Medica Bulgarica
Acenocoumarol, a 4-hydroxycoumarin derivative, is widely prescribed for the primary and secondary prevention of thromboembolic disorders. Maintenance dosing of acenocoumarol is significantly influenced by polymorphic variants in the CYP2C9 and VKORC1 ...
Tzveova R., Saraeva R., Dimitrova-Karamfilova A., Nachev G., Mitev V., Kaneva R., Pendicheva-Duhlenska D.   +6 more
doaj   +1 more source

The role of pharmacogenetics in personalizing anticoagulant therapy: data from the Astrakhan region

Фармация и фармакология (Пятигорск)
The metabolic characteristics of anticoagulants largely depend on the patient’s genetic profile, determining the variability of pharmacological response to drugs and the risk of adverse reactions.
A. N. Romanova, B. I. Kantemirova, O. V. Komarova, N. V. Timofeeva   +3 more
doaj   +1 more source

Gene expression of anticoagulant rodenticide target genes (vkorc1 and vkorc1l1) in a non-target wildlife species: The eagle owl (Bubo bubo)

Ecotoxicology and Environmental Safety
Anticoagulant rodenticides (ARs) are globally used for rodent control, posing significant risks to non-target predators and scavengers through secondary poisoning.
Livia Spadetto, Pilar Gómez-Ramírez, Antonio Juan García-Fernández, Mario León-Ortega, José Manuel Zamora-Marín, Antonio Zamora-López, José Francisco Calvo, José Antonio Rodríguez-Martín, José María Navas, Azucena Bermejo-Nogales   +9 more
doaj   +1 more source

VKORC1 Gene [PDF]

, 2020
openaire   +1 more source